Closely-held Ripple Therapeutics named Jonathan Talamo, M.D., an internationally known ophthalmologist, innovator and consultant to the industry with more than 25 years of experience in healthcare, to the board.
Dr. Talamo is the former CMO and worldwide VP of clinical and medical affairs at Johnson and Johnson Vision. He also served as CMO with Ocular Therapeutix, where he oversaw clinical development programs in multiple therapeutic areas, including post–cataract surgery inflammation, dry eye, allergy, glaucoma and retinal vascular diseases.
In a statement, Dr. Talamo said that as a long-time practicing ophthalmologist who has also worked in industry to develop extended-release ophthalmic medications, “I know there are huge unmet needs for patients across multiple disease states.”
Tom Reeves, president and CEO of Ripple, said Dr. Talamo brings a unique combination of clinical expertise as a practicing ophthalmologist and industry experience with both large and small companies.
“He will be a great asset for Ripple as we look to realize on our vision of providing safe and effective treatment options for patients with sight-threatening conditions,” Mr. Reeves added.
